Development of anti-VEGF prolonged release drug delivery system containing PLL dendrimer and hyaluronic acid
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Maik Nauka/Interperiodica/Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
In this study we aimed to develop anti-vascular endothelial growth factors (anti-VEGF) drug delivery systems that long-term sustained release using dendrimer technology and to evaluate its possible cytotoxic effects on the retina pigment epithelial cells (ARPE-19) and the irritation potential by Hen's Egg Test on a chorioallantoic membrane (HET-CAM) analysis. The drug carrier gel formulation was prepared by adding hyaluronic acid (HA) after bevacizumab (BEV) was complexed with poly-L-lysine (PLL) dendrimer. The formulations were determined by the particle size, polydispersity index (PDI) values, zeta potential, pH, optical clarity, and their content. The UV- spectrophotometric analytical methods were developed, validated and applied for the kinetic studies. Prolonged BEV release from formulations has been observed for up to 21 days. Cell viability was evaluated with the XTT assay. VEGF and BEV levels in the medium were measured using a human VEGF and BEV ELISA kit, respectively. HET-CAM assays were conducted to determine the irritation potential. The clarity of gel formulation was found to be clear and satisfactory (double +). The pH of gel formulation ranged between 6.39 and 6.95. The zeta potential of formulations ranged between +3.9 and -1.5 mV. The particle size of formulations ranged between 15 and 302 nm. The loading efficiency (LE) of the complex formulation was found 79.04%. The formulation's kinetic behavior was determined by the Higuchi and Korsmeyer-Peppas model. The formulations did not cause any irritation. According to the results obtained, gel formulation was innovative, effective and suitable for treatment. However, animal experiments and clinical studies should also be performed.
Açıklama
This work was supported by Trakya University Scientific Research Projects Unit (Grant no. 2018/196).
Anahtar Kelimeler
Anti-VEGF, Bevacizumab, Poly-L-Iysine Dendrimer, Bevacizumab Avastin, Intravitreal, Complexes
Kaynak
Russian Journal of Bioorganic Chemistry
WoS Q Değeri
Q4
Scopus Q Değeri
Q4
Cilt
48
Sayı
6
Künye
Gedik, G., Oztabag, C. K., Sarp, O., Nazli, H., Tiranbesli, G., Kurt, A. H., ... & Ayaz, L. (2022). Development of Anti-VEGF Prolonged Release Drug Delivery System Containing PLL Dendrimer and Hyaluronic Acid. Russian Journal of Bioorganic Chemistry, 48(6), 1348-1361.
